Somewhat Positive News Coverage Somewhat Unlikely to Impact ACADIA Pharmaceuticals (ACAD) Stock Price
News headlines about ACADIA Pharmaceuticals (NASDAQ:ACAD) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.7169110417686 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- J P Morgan Chase & Co Analysts Give ACADIA Pharmaceuticals Inc. (ACAD) a $50.00 Price Target (americanbankingnews.com)
- This Hedge Fund Manager Thinks The Market May Increase 30% By December 2018 (insidermonkey.com)
- ACADIA Pharmaceuticals Inc. (ACAD) Receives “Neutral” Rating from Goldman Sachs Group, Inc. (The) (americanbankingnews.com)
- ACADIA Pharmaceuticals Inc. (ACAD) EVP Glenn Baity Sells 37,500 Shares (americanbankingnews.com)
- Pros And Cons Of All The News Out Of Acadia Pharma This Week – Benzinga (benzinga.com)
Several equities research analysts recently weighed in on ACAD shares. BidaskClub raised ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 21st. Zacks Investment Research raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a report on Tuesday, July 11th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday, August 9th. Cowen and Company reissued an “outperform” rating and issued a $46.00 price objective (up previously from $42.00) on shares of ACADIA Pharmaceuticals in a report on Thursday, August 10th. Finally, ValuEngine raised ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, August 10th. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. ACADIA Pharmaceuticals has a consensus rating of “Buy” and an average price target of $46.21.
Shares of ACADIA Pharmaceuticals (NASDAQ ACAD) opened at 38.54 on Monday. The stock’s market cap is $4.72 billion. The company has a 50-day moving average price of $36.00 and a 200 day moving average price of $31.68. ACADIA Pharmaceuticals has a one year low of $20.68 and a one year high of $41.20.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.17. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. The firm had revenue of $30.50 million for the quarter, compared to the consensus estimate of $20.02 million. During the same quarter last year, the company earned ($0.63) earnings per share. The business’s revenue for the quarter was up 30400.0% compared to the same quarter last year. Equities research analysts expect that ACADIA Pharmaceuticals will post ($2.53) earnings per share for the current year.
In other news, EVP Glenn Baity sold 14,322 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $34.88, for a total value of $499,551.36. Following the transaction, the executive vice president now owns 78,578 shares of the company’s stock, valued at $2,740,800.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 116,426 shares of company stock worth $4,100,885 in the last ninety days. Corporate insiders own 22.25% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/10/09/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-acadia-pharmaceuticals-acad-stock-price.html.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Stock Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.